Pan Immune Inflammation Value for Perioperative Complications of Laparoscopic Sleeve Gastrectomy

Completed

• Conditions: Morbid Obesity; Laparoscopic Sleeve Gastrectomy; Post Operative Complicaiton
• Interventions: Procedure: Laparoscopic Sleeve Gastrectomy

• Registration Number: NCT06284356
• Lead Sponsor: Kahramanmaras Sutcu Imam University

Brief Summary

Morbid obesity emerges as a problem that causes serious complications and increased mortality rates. The most effective treatment for morbid obesity today is surgical treatment. The most preferred type of surgery in morbid obesity surgery in Turkey and around the world is Laparoscopic Sleeve Gastrectomy (LSG).

While postoperative complications are divided into early and late complications, complications that develop during surgery and in the postoperative period before discharge are defined as perioperative complications. Early surgical complications after LSG include complications such as staple line bleeding, leaks, pulmonary thromboembolism, and torsion of the remnant stomach. It is important to detect these complications, which can be controlled with early intervention in the perioperative period.

Monitoring blood parameters and monitoring inflammation are methods that are easily accessible and provide rapid evaluation. Platelet lymphocyte ratio (PLR) and neutrophil-lymphocyte ratio (NLR), which are used in the evaluation and detection of postoperative complications, have shed light on studies in this direction. Pan immune inflammation value (PIV) is calculated from blood parameters and has been used to evaluate prognosis and chemotherapy results in colorectal cancer.

In this study, the diagnostic importance of changes in NLR, PLR, and PIV values in the preoperative and postoperative periods will be investigated in detecting complications that develop in the perioperative period before discharge in patients who underwent LSG.

Detailed Description

Patients who will undergo LSG due to morbid obesity will be included in the study. Patients who are completely healthy, not morbidly obese, and have no additional disease will be taken as the control group. Reference range values will be obtained by taking a complete blood count from the control group once. From patients who will undergo LSG, routine pre-operative complete blood count values, and postoperative 24th-hour complete blood count values will be taken. PLR, NLR, and PIV will be calculated manually from these complete blood count samples and the change in these parameters will be evaluated between patients who develop complications and those who do not.

In descriptive statistics, categorical data will be given as number (n) and percentage (%). Numerical data will be given as mean ± standard deviation (SD) (minimum-maximum data) or median (25% - 75% values) depending on their compliance with normal distribution. The Kolmogorov-Simirnov test will be used to determine the distribution of normality. A p-value \<0.05 is accepted as statistically significant.

Study Timeline

• Study Start: 2022-05-01
• Primary Completion: 2023-05-01
• Study Completion: 2023-05-01
• Study First Submitted: 2024-01-20
• Status Verified: 2024-02
• Study First Submitted QC: 2024-02-21
• Study First Posted: 2024-02-28
• Last Update Submitted: 2024-02-28
• Last Update Posted: 2024-03-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 159

Inclusion Criteria

• Completely normal, healthy individuals with no additional diseases and BMI values of 19-24 kg/m2 for the control group
• Older than 18 years who will undergo Laparoscopic Sleeve Gastrectomy
• Patients with a body mass index (BMI) value ≥ 40 kg/m2 and no known comorbidities
• Patients with a BMI value ≥ 35 kg/m2 and additional comorbid diseases (such as Diabetes, Hypertension, Asthma, and Chronic Obstructive Pulmonary Disease)

Exclusion Criteria

• Individuals under 18 years of age and morbid obesity patients
• Patients who indicate elective surgery due to morbid obesity and who are planning for non-LSG morbid obesity surgery
• Patients who do not want to participate in the study
• Patients with additional diseases such as concurrent malignancy or rheumatological disease

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with complications after LSG	Laparoscopic Sleeve Gastrectomy	-
Patients without complications after LSG	Laparoscopic Sleeve Gastrectomy	-

Primary Outcome Measures

Name	Time	Method
Complication prediction after LSG with complete blood cell parameters	2022-2023	Blood sample changes after LSG with complete blood cell parameters

Trial Locations

Locations (1)

Kahramanmaras SIU; 🇹🇷 Kahramanmaraş, Turkey